An International Approach With its head office in Berlin, branch offices in Munich and Buenos Aires CH KILGER offers a truly international approach providing a global IP service to its clients. The Munich office serves also for the preparation of the frequent oral proceedings CH KILGER takes part in. In Buenos Aires CH KILGER coordinates its Latin America services. The patent attorneys are highly specialized and strategic in their approach. A Wingspan of Expertise CH KILGER provides IP services ranging from trademark and patent prosecution, patent infringement and litigation, due diligence work, freedom-to-operate analyses, to opinion work and IP-sales/licensing transactions. CH KILGER can assist you in all technical areas such as the chemical, electrical, nanotechnology, food, biotechnology and pharmaceutical or the engineering fields. Strong scientific backgrounds, as well as years of legal experience working with the European Patent Office, the Latin American patent offices, top-tier international law firms and in-house counsel, mean the CH KILGER lawyers understand their technical, business, and legal goals. Our interdisciplinary approach leads to best possible synergies for our clients. Our Clients and Colleagues CH KILGER represents an international clientele of inventors as well as investors working with the most recent high-tech technologies. The clients range from multinational pharmaceutical corporations to start ups in various fields such as nanotechnology, microfluidics, polymer chemistry and biotechnology. Clients and colleagues have praised the firm for its exquisite work.
Certest Biotec
Certest Biotec, established in Spain in 2002 as an innovative and technology-based company, has always based its growth on the research and development of new products, and the exploration for new market niches and opportunities. The key to understand its success is the way to understand its organization: highly specialized and customer oriented. Certest Pharma part of Certest Biotec, is dedicated to building a platform for the development of RNA vaccines and oligotherapeutics, with a special focus on seeking improved formulations to enhance delivery. In that sense, Certest Pharma is specialized in the development of raw materials, amongst which lipids and more specifically, ionizable lipids, are one of the leading products. Certest´s Pharma three main areas are: Delivery technology: Ionizable lipids are a key element in the production of lipid nanoparticles (LNPs), and as such, have been widely used for the systemic delivery of RNA therapeutics. After the screening of more than a thousand ionizable lipids with our semi-rational design we are able to offer outperforming and custom made ionizable lipids for the effective targeted delivery of RNA therapeutics. API platform: This platform will cover, thanks to over 20 years of experience in the field, all the necessary steps for the design, development, and evaluation of effective mRNA and oligotherapeutics molecules. Also, a proprietary UTR sequence and codon optimization software have been developed showing higher results in protein expression. Enzymes for the production of mRNA have also been developed. Therapeutic products: Bringing together both areas Certest was granted to develop a new booster for TB vaccine and therefore be able to show the full capabilities of the company.
Cerba Research
Cerba Research is a global specialty laboratory partner dedicated to advancing oncology drug development. Combining deep scientific expertise with a comprehensive suite of specialty lab solutions including genomics, immunology, histopathology, flow cytometry, and biomarker development. Cerba Research delivers high-quality, actionable insights across the entire clinical trial lifecycle. With integrated specialty and central lab capabilities, advanced technologies, and a strong operational footprint worldwide. Cerba Research empowers pharma and biotech innovators to design smarter studies, unlock complex tumor biology, and accelerate the delivery of new cancer therapies to patients.
Cellular Technology Limited (C.T.L.)
Cellular Technology Limited, (CTL) is a leading solution provider for immune monitoring supporting both research, pre-clinical and clinical studies phase I, II, III, IV and commercial. We help you to get the best possible, most reliable results, by offering a wide range of products and services, including: CONTRACT LABORATORY SERVICES: Our CLEP/CLIA-certified laboratory can provide logistics (USA as well as globally), cryopreservation of functional PBMC from whole blood (serves as central blood processing laboratory in North America), ELISPOT, ELISA, NAb, multiplex Cytokine Bead Arrays (CBA), Flow Cytometry (phenotyping, ICS, multimer readouts etc.), Killer assays, MAT and more. CTL is developing, validating and performing low and high-throughput format testing, tailored to our clients’ needs. INSTRUMENTATION: Image analyzers (ImmunoSpot®), high-throughput Analysis/Counting: ELISPOT, FluoroSpot, NK Assays, Viral Plaque (PRNT, FRNT, FFA), Bactericidal, Microbial Colony Counting, Genotoxic (MLA, AMES), Yeast Viability analysis, Stem Cell Assays and more…. CONSUMABLES: Cryopreserved functional PBMC: Over 150 HLA-typed donors with established reactivity to TH1/Th2 analytes to HLA Class I & Class II-restricted antigens. B and T Cell ELISPOT Kits to multiple species, FluoroSpot Kits ranging from single to multiplexed 4-color analytes and serum-free media, cryopreservation standardization solutions for functional PBMC generation and more…
cellNUA KSA
cellNUA is a biotechnology company transforming how the world approaches infectious disease, immune dysfunction, and cellular regeneration—by unlocking the therapeutic intelligence of nature itself. Founded in Galway, Ireland, with a growing international presence, cellNUA merges evolutionary biology, nanomedicine, and advanced bioinformatics to create naturally inspired, scientifically validated interventions. At its core is a belief that the cell is not a passive victim of disease, but an active architect of its own defense. Our goal is to decode the biochemical logic that governs this cellular resilience and translate it into scalable healthcare platforms. Our flagship platform, BEEMAR™, is the first immune system technology built on comparative glyco-genomics between honeybees and humans. It harnesses the honeybee’s highly evolved immune response—one that is faster than human immunity and uniquely precise—alongside regenerative compounds from marine ecosystems. Through proprietary inoculation and extraction protocols, BEEMAR™ produces pathogen-specific biologics that target viruses, bacteria, and parasites without relying on traditional synthetic drugs. Preclinical trials have shown remarkable reductions in viral load—including against COVID-19, polio, and herpes—and significant inhibition of the malaria parasite, all with no observed cytotoxicity. Supporting platforms like CellMar78™ and Occunase™ extend our approach from therapeutic to preventative medicine. CellMar78™ is a marine-derived, isotonic delivery medium designed for safe gene therapy, stem cell support, and regenerative research. Occunase™, a drug-free nasal spray, forms a mechanical barrier in the nasal mucosa to block respiratory pathogens and allergens—a practical, immune-independent defense for public health. cellNUA’s research is rooted in deep omics analysis, high-throughput screening, and a platform-based architecture that allows rapid adaptation to emerging threats. Our partnerships with institutions such as Johns Hopkins University and Trinity College Dublin, as well as preclinical validations in Europe and Africa, reinforce our commitment to rigorous science and global health equity. With a vision to localize biotech solutions through decentralized “BioCities,” beginning in Europe and the Middle East, we aim to reduce global dependence on imported therapeutics and empower regions with rapid-response health infrastructure. Our work is not only about treatments—it is about restoring trust in biology’s original intelligence and equipping humanity with systems that are proactive, precise, and profoundly sustainable. cellNUA: Where Nature’s Intelligence Becomes the Blueprint for Modern Medicine.
Celestia Diagnostics
Celestia Diagnostics develops lab tests and clinical bioinformatics systems to aid in the diagnosis and treatment of chronic complex conditions such as Long COVID, ME/CFS, and POTS.
Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company focused on improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first and is committed to empowering healthcare providers and patients with the goal of improved health outcomes. Primarily focused on dermatologic cancers and gastroenterological disease, Castle’s innovative tests are designed to help answer critical clinical questions and address treatment plan challenges facing clinicians to better inform patient care decisions. Castle’s current portfolio consists of tests for skin cancers, Barrett’s esophagus and uveal melanoma. Additionally, the Company has active research and development programs for tests in these and other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis seeking biologic treatment. Using its expertise in advanced technologies, such as genomics, spatialomics, data analytics and artificial intelligence, Castle digs deep into treatment pathways to develop personalized, clinically actionable tests that can improve, and potentially transform, the management of diseases and patient outcomes. | At Castle, it all comes down to people. After all, disease doesn’t just happen — it happens to people. We believe that disease management and treatment decisions can be better informed through a person’s unique biology, which is revealed through the scientific rigor of our innovative tests. We are committed to empowering healthcare providers and patients with the goal of improved outcomes.
Carestream Health
We’re A Customer-Focused Company. Carestream Health is passionately committed to doing all the right things to help our customers be successful. We provide high-value technology, solutions and services through engaged employees who drive continuous innovation and operational excellence. The work we do matters. In medical imaging, we are relentless in our pursuit of providing superb image quality that can help enrich patient care. Medical providers throughout the world rely on our medical imaging solutions to help them make informed diagnoses. Our broad portfolio of imaging products and solutions offers facilities of all sizes – from clinics and single hospitals to large healthcare networks – a choice of features and options so they can choose the solution that best fits their workflow and their budget today, with the capability to expand in the future as their needs change. We also offer general X-ray solutions for the veterinary market. Additionally, we serve industrial markets around the world with our non-destructive testing (NDT) products. Our NDT customer-focused development teams continually work to make sure our NDT products can perform high-quality radiographic testing anywhere in the world. This testing helps to help create a safer life for people through the inspection of critical components in aerospace, transportation, oil and gas, mining and energy industries. We also partner with progressive companies to commercialize customer-focused products by applying our precision roll-to-roll coating processes and large-scale manufacturing facilities for market opportunities that include energy, storage, electronics, displays, automotive components and much more